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Abstract
Background The Self Assessment Vitiligo Extent Score (SA-VES) is a validated, patient-reported outcome measure to
assess the body surface area affected with vitiligo. Information on how to translate the obtained score into extent, sever-
ity and impact strata (mild–moderate–severe) is still lacking. Stratification is helpful to define inclusion criteria for trials,
enables comparison and pooling of trial results and can be used for epidemiological research.
Objectives The aim was to develop extent, severity and impact strata for the SA-VES based on validated anchor-
based questions.
Methods In total, 315 patients with vitiligo (non-segmental; age ≥ 16) recruited at the Ghent University Hospital (Bel-
gium) completed a questionnaire that was conducted in cooperation with the Dutch Society for vitiligo patients to ensure
content validity. First three anchor questions included in the questionnaire [Patient Global Assessment (PtGA) for vitiligo
extent, severity and impact] were assessed for content validity, construct validity and intrarater reliability. Subsequently,
the PtGAs were used to stratify the SA-VES based on ROC analysis.
Results For all PtGAs (PtGA extent, PtGA severity, PtGA impact), at least 75% of hypotheses evaluated for construct
validity were confirmed. Intrarater reliability of all PtGAs was good to excellent (ICCs PtGA extent: 0.623; PtGA severity:
0.828; PtGA impact: 0.851). The optimal cut-off values of the SA-VES between the three global categories (mild/limited –
moderate – severe/extensive) were 1.05% and 6.45% based on PtGA extent, 2.07% and 4.8% based on PtGA severity
and 2% and 3.35% based on PtGA impact.
Conclusion This study provides the first guide for the interpretation of the numerical output obtained by the SA-VES
(vitiligo extent) and enables the translation into a global vitiligo grading for extent, severity and impact. As patients’ inter-
pretation of vitiligo extent, severity and impact may vary amongst patients worldwide, future international studies will be
required.
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Background
The Self Assessment Vitiligo Extent Score (SA-VES) is a vali-
dated, patient-reported outcome measure for monitoring vitiligo
extent. It is based on an assessment of the affected body surface
area (BSA) which is considered to be a relevant outcome in the
assessment of vitiligo severity. It is a patient-reported version of
the Vitiligo Extent Score (VES) for physicians.1 Information on
how to translate the obtained VES scores into disease severity
strata from the physicians’ point of view has been described
recently while this is still lacking for the patient-reported version
(SA-VES).2 Stratification can be used to define inclusion criteria
for clinical trials, epidemiological research and is important for
correct comparison and pooling of trial results. The process to
stratify the numeric output of an instrument into categories
(mild–moderate–severe) is usually based on an ‘anchor ques-
tion’ (e.g. Patient Global Assessment) that is preferably validated
in advance.3,4 A validated Patient Global Assessment for vitiligo
is, however, lacking. A validated Global Assessment instrument
could also be used as an anchor question for the interpretation
and stratification of other outcome measure in vitiligo ([e.g.
Dermatology Life Quality Index (DLQI), Vitiligo Impact Patient
scale (VIPs)].).5–7
The first aim of this study was to assess the content validity,
construct validity and intrarater reliability of a Patient Global
Assessment (PtGA) for disease extent, severity and impact. The
second aim was to determine strata (mild–moderate and severe)
for the SA-VES based on the validated PtGA for extent, severity
and impact.
Materials and methods
Study design and ethics
In this observational study, patients with vitiligo (non-segmen-
tal) age ≥16 were consecutively recruited at the Ghent University
Hospital (Belgium) (October 2017–beginning of October 2019)
and were asked to complete a Dutch questionnaire including the
SA-VES as well as a 5-point global assessment scale for extent
(PtGA extent), severity (PtGA severity) and impact (PtGA
impact) (Fig. 1).
In the preparative stage of this study, the PtGA instruments
were evaluated and modified by several members of the Dutch
Society for Vitiligo patients (vitiligo.nl) to ensure the content
validity. The patients’ global assessment instruments were subse-
quently evaluated by asking the relevance, completeness and
comprehensibility of the items included. The questions used to
assess the Patients Reported Global Assessment were pilot tested
at the department of dermatology in Ghent. The COSMIN
checklist was used as a guidance for designing and reporting our
study.8,9 This study was approved at the local ethics committee
(reference number: B670201421409), and written informed con-
sent was obtained from all patients who completed the question-
naire. The cooperation with the Dutch Society for vitiligo
patients (Vitiligo.nl) was reported at the Amsterdam Medical
Center (W17_355#17.413).
Validity and reliability
Construct validity of the PtGA instruments was evaluated by
testing at least four predefined hypotheses by Spearman correla-
tions with other PROMs (e.g. SA-VES, DLQI, impact score 0–10
and the PtGA scores included in this study) (Appendix S1).10 As
an impact score from 0 to 10 was also included to evaluate con-
struct validity of the PtGA score, this impact score 0–10 was also
validated for use (Appendix S1). To evaluate the intrarater (test–
retest) reliability of the PtGA instruments and impact score 0–
10, a subgroup of patients was asked to complete the question-
naire twice with an interval of 2 weeks. To increase the usability
of the PtGA in an international setting, all related questions were
translated (including 2 forward and 2 backward translations) in
English (Fig. 1) by a professional translation agency (ElaN Lan-
guages, Heusden-Zolder, Belgium) following the instructions for
translations of measurement instruments as a guidance.11 All
questions (PtGA and impact score 0–10; including translated
version) used for this study are available on request at the corre-
sponding author.
Stratification of affected self-assessed body surface area
(SA-VES)
In the second part of this study, the validated PtGA for extent,
severity and impact (Fig. 1) was used as anchor questions to
stratify the SA-VES. By this anchor-based approach, the SA-VES
outcomes were compared (anchored) to the results of Patient
Global Assessments collected at the same time. By defining the
thresholds based on ROC analyses, the SA-VES could be strati-
fied into global strata (mild–moderate–severe).
Statistics/data analysis
Statistical analyses were performed using SPSS 25.0 (SPSS
Science, Chicago, IL, USA). The intrarater agreement of the
PtGA scores was calculated by ICC and reported as single mea-
sures [two way mixed, absolute agreement]. The following
guidelines for the interpretation of the ICC were used as follows:
below 0.4 considered as poor, between 0.4 and 0.59 as fair,
between 0.6 and 0.74 as good, and ≥0.75 as excellent. A cut-off
point of a Spearman’s correlation of at least 0.4 was used in all
hypotheses used to test construct validity (Appendix S1). Paired
analysis was performed using Wilcoxon signed-rank test. Global
strata (cut-off points) for the SA-VES were based on Youden’s
index assessed by ROC analyses using MedCalc v19.2.5. software
(Medcalc, Mariakerke, Belgium). MedCalc was also used to
assess the 95% CI for the median of the SAVES scores per sever-
ity strata for each PtGA (extent, severity and impact). To check
the degree of agreement between the obtained severity strata
(ranges of cut-off points) and the PtGAs, the intraclass correla-
tion coefficients (ICCs) were subsequently assessed. Missing
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values were excluded from the final analysis. For the DLQI score,
if some questions were left unanswered this was scored 0. How-
ever, the questionnaire was not scored in case the questionnaire
was considered not to be finalized by the patient (e.g. half of all
questions left unanswered). In all cases, significance level was set
at P < 0.05.
Results
Preparative stage (content validity PtGAs)
A draft version of the PtGA questions was thoroughly checked
and modified multiple times according to the patients’ prefer-
ences (7 members of Dutch society for vitiligo patients), based
on completeness, comprehensibility and relevance. Based on the
patient’s comments, the question that introduced the rating of
the patients’ global assessment of severity (PtGA severity) was
modified to a more detailed and comprehensible version for
patients in order to rate their vitiligo severity without further
explanation (Fig. 1). This detailed version illustrated more the
different dimension of the PtGA severity compared to the PtGA
for impact and extent. The question included in the global
impact score was clarified by adding the word ‘influence’.
Reliability and construct validity of PtGA scores
In total, 315 patients (age ≥ 16) were included [male/female
43.5%/56.5%; mean age (SD) at inclusion was 40  14 years,
range 16–73 years]; photo skin types: I (1.4%, 4/289), II (36%,
104/289), III (48.1%, 139/289), IV (12.1%, 35/289) and V (2.4%,
7/289); median (mean) BSA (SA-VES) score was 1.65% (4.27%)
(range 0.04–73.88%); and median DLQI score was 2 (range 0–
21).
Supporting evidence for construct validity was provided for
PtGA extent, PtGA severity, PtGA impact and impact score 0-10
as at least 75% of hypotheses (Appendix S1) per instrument were
confirmed (Table 1). All Spearman correlations included in the
hypotheses were significant, although 2 did not reach the cut-off
level of 0.4. Highest correlation coefficients for the global assess-
ment of severity (PtGAs) were observed with PtGA impact
(r = 0.729). The different dimension of the PtGA severity com-
pared to the PtGA impact was, however, confirmed by a paired
analysis showing a highly significant difference (P < 0.001). In
total, 111/287(38.7%) patients rated impact and severity differ-
ently with most patients reporting a higher severity compared to
impact (75/111, 67.6%). Not surprisingly, the correlation
between DLQI was strongest for PtGA impact (r = 0.598), fol-
lowed by PtGA severity (r = 0.489) and PtGA extent
(r = 0.411). For extent (PtGA extent), highest correlation coeffi-
cients were observed with the SA-VES (r = 0.633) followed by
PtGA severity (r = 0.586).
Fifty patients were included for the test–retest study. Test–ret-
est results of the PtGA extent [n = 50; ICC = 0.623 (95% CI:
0.418–0.768)], PtGA severity [n = 50; ICC = 0.828 (95% CI:
0.716–0.898)], PtGA impact [n = 48; ICC = 0.851 (95% CI:
0.749–0.914)] and impact score 0-10 [n = 34; ICC = 0.872
Figure 1 Translations Patient Global Assessments from original
Dutch version. Remark related to Patient Global Assessment for
severity: the wording “skin colour” was added at the last stage of
the translation but was not included in the original Dutch version.
Within the Dutch version we considered this to be clear as an addi-
tional question related to different skin types “(I-VI)” was included
in the same questionnaire in the majority of cases. In a minority of
cases skin type was assessed by the physician for instance if the
self assessment question related to skin type was not included in
the questionnaire.”
Table 1 Correlations including those used for the construct validity testing of PtGAs and impact score 0–10
Spearman’s correlations (rho)
Included in the construct validity test
PtGA extent PtGA severity PtGA impact DLQI SA-VES Impact score 0-10
PtGA extent NA 0.586* 0.479* 0.411* 0.633* 0.455
PtGA severity 0.586* NA 0.729* 0.489* 0.442* 0.712
PtGA impact 0.479* 0.729* NA 0.598* 0.359* 0.876
Impact score 0-10 0.455* 0.712* 0.876* 0.601* 0.350* NA
*Significant at 0.01 level; boxes in light grey: correlations not included in the hypotheses used for construct validity testing. Cut-off level for rho’s correlation of
0.4 not reached for two correlations. Number of patients included for the correlation test ranged between 199 and 291.
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(95% CI: 0.760–0.934)] demonstrated all good to excellent test–
retest intraclass correlation coefficients.
Stratification of SA-VES
Median estimation of the PtGA severity was scored as ‘moder-
ate’. Most patients (mode) reported ‘limited extent’ of their viti-
ligo (58.3%, 169/290). About 207 patients (72.1%, 207/287)
reported a mild-to-moderate impact of vitiligo, 53 (18.5%, 53/
287) reported severe-to-very severe influence of vitiligo on their
quality of life. Table 2 shows the optimal cut-off points and con-
fidence interval of the SA-VES per three categories based on the
respective anchor questions (PtGA extent, PtGA severity, PtGA
impact). The optimal cut-off values of the SA-VES between the
three global categories (1. mild/limited, 2. moderate and 3. sev-
ere/extensive) were 1.05% and 6.45% based on PtGA extent,
2.07% and 4.8% based on PtGA severity and 2% and 3.35%
based on PtGA impact. ICCs between obtained cut-off point
ranges and PtGAs for extent, severity and impact are included in
Table 2.
Box plots for PtGA for extent, severity and impact represent-
ing three categories (mild – moderate – severe) based on SA-
VES are presented in Fig. 2a–c.
The median, the IQR and 95% CI of the median, of the SA-
VES per category of the PtGA extent, PtGA severity and PtGA
impact are presented in Table 3.
Discussion
In this study, we validated a PtGA for extent, severity and impact
using a simple scoring system based on a global assessment ques-
tion. The PtGA is an intuitive and simple measure that is often
used in clinical trials. The PtGAs were used to stratify the
numeric score obtained by the SA-VES. Stratification of out-
come measures is crucial to interpreted the obtained scores and
to perform research on homogenous study populations. Here,
we confirm the intrarater reliability and construct validity of
three PtGAs based on hypotheses testing. Using the validated
PtGA-anchor questions, the possible strata per category could be
assessed for the SA-VES score. Based on the cut-off values, an
affected body surface area (SA-VES) of more than 1.05% and
6.45% was already considered as moderate extensive and exten-
sive, respectively. The median SA-VES score for moderate exten-
sive and extensive was 2.740 and 9.370, respectively. Cut-off
values for PtGA severity were different compared to PtGA
extent, emphasizing the importance of separating these two
aspects in future trials.
Severity assessment requires an additional dimension from
patient’s point of view including additional influencing factors
such as location of the lesions or patients’ photo skin type espe-
cially for a pigmentary disorder like vitiligo. Insight into
patients’ experiences is crucial to properly define severity in a
way that is both useful to the physician and reflective of the
patient’s status. A thorough investigation within a large vitiligo
patient population may offer additional criteria to better define
vitiligo severity.
Impact assessment involves a different dimension as it mea-
sures the individual experience of the influence of the disease on
daily life. This may be a crucial factor in the therapeutic choice
during a vitiligo consultation. Interestingly, >1/3 patients rated
impact and severity differently indicating that patients recognize
that the more objective concept of severity may result in a differ-
ent subjective impact from one patient to another. Stratification
based on PtGA for impact indicated that even a low-affected
BSA (SA-VES) of 3.35% can have a high to very high impact on
the quality of life. Conversely, a very high SA-VES can have a
moderate impact. This is also clearly illustrated by the distribu-
tion of outliers of BSA >32% in the box plots, in which most
variation within the 3 categories is present for ‘impact’ (PtGA
impact), followed by ‘severity’ (PtGA severity), while all highest
Table 2 Cut-off points/severity strata for the SA-VES into three categories
Affected body surface area % (SA-VES)
PtGA extent No vitiligo any more– limited Moderate Extensive – very extensive
Range ≤1.05% >1.05%–6.45% >6.45%
Cut-off
ICC = 0.642
1.05% (0.91–2.78) 6.45% (3.13–10.83)
PtGA severity Not severe at all–mild Moderate Severe – very severe




PtGA impact No impact –mild impact* Moderate impact** High impact- very high impact***
Range ≤2% >2%–3.35% >3.35%
Cut-off
ICC = 0.311
2% (0.61–3.99) 3.35% (0.25–6.15)
ICC, intraclass correlation between obtained ranges per strata and PtGAs; PtGA, Patients reported global assessment; SA-VES, Self Assessment Vitiligo
Extent Score. *In the questionnaire the wording was "no influence at all - little influence". **In the questionnaire the wording was "moderate influence".***In the
questionnaire the wording was "severe influence - very severe influence".
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outliers are included in the highest category for ‘extent’ (PtGA
extent). This points again the importance to differentiate these
three domains. An added value of the validated PtGA scores is
that they may be used to stratify outcomes of other scores. In
addition, they can be helpful in the clinic or trials to provide
information ‘at a glance’. However, for studies investigating the
impact of the disease more in-depth, a detailed questionnaire is
recommended [e.g. VIPs, DLQI, vitiligo-specific quality-of-life
instrument (VitiQoL)] to ensure the required information.7,12
To check the relevance of outliers, a sensitivity analysis was per-
formed. Correlations were performed including and excluding
the seven outliers which provided similar results.
A strength of this study was that patients were involved in the
construction of the questions used to assess the PtGA for extent,
severity and extent. However, for future studies, a diversity (e.g.
different ethnic backgrounds) in patients’ population participat-
ing in the construction of the PtGA questions should be pursued
to ensure generalization of its use.
Another important limitation of this study was the single-cen-
tre setting including most often Caucasian photo skin types with
rather limited BSA involvement. This study should therefore be
repeated within different centres including patients of darker
skin types (IV–VI) and more variation in extent. Future studies
are required to confirm other measurement properties such as
responsiveness and cross-cultural validity. Moreover, it could be
interesting to compare the physicians’ point of view with the
patients’ point of view related to the global assessments of extent
and severity and related to the stratification into categories (by
using VES) within the same population in future studies.
In conclusion, this study confirmed the content validity, con-
struct validity and intrarater reliability of the PtGA for extent,
severity and impact. These tools can be used for the interpreta-
tion and stratification of scores obtained with other patient-re-
ported outcome measures (PROMs) and can guide treatment
decisions in vitiligo management.
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Figure 2 (a) Box plots for SA-VES representing three categories
(limited –moderate – extensive) based on PtGA extent. (b)
Box plots for SA-VES representing three categories (mild –
moderate – severe) based on PtGA severity. (c) Box plots for
SA-VES representing three categories (little –moderate – severe)
based on PtGA impact. (d) Boxplots for SA-VES representing three
categories (limited-moderate-extensive) based on PtGA extent on
a different scale (Y axis on 40). The first category (1) in the boxplots
of each PtGA also includes "no vitiligo any more/not at all severe/
no influende at all" and the third (3) category also includes "very
extensive/very severe/very severe influence".
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Appendix S1. For review
Table 3 Median SAVES scores for each PtGA for 3 and 4 categories of extent, severity and impact.
PtGA categories N Median SAVES (%) IQR 95% CI for the median†
PtGA extent
No vitiligo-limited 163 0.78 0.315-1.915 0.678–1.032
Limited 159 0.790 0.335–1.915 0.692–1.040
Moderate 72 2.740 1.3938–5.3838 2.033–3.580
Extensive 28 9.370 4.210–16.3225 5.185–13.631
Very extensive 9 20.235* (mean 33.745) 11.3475–58.250 10.911–63.771
Extensive & very extensive 37 11.935 5.465–19.6475 7.752–16.808
PtGA severity
Not severe- mild 113 0.790 0.315-1.8875 0.587–1.141
Mild 85 0.985 0.3775–2.0325 0.700–1.305
Moderate 96 2.2325 0.821–4.740 1.518–3.128
Severe 52 4.675 1.581–10.7225 2.425–7.057
Very severe 11 1.580* (mean 14.8477) 0.655–15.00 0.641–21.402
Severe & very severe 63 4.475 1.220–10.780 2.140–6.454
PtGA impact (influence)
No impact-little 143 1.035 0.370–2.425 0.780–1.486
Little 118 1.2875 0.385–2.486 0.892–1.657
Moderate 74 2.2425 0.9313–5.4163 1.430–3.349
Severe 41 5.060 1.86–10.5025 3.472– 7.707
Very severe 10 1.175* (mean 6.073) 0.530–4.5887 0.480–7.288
Severe & very severe 51 4.225 1.225–10.350 2.136–6.455
CI, confidence interval; IQR: interquartile range.
*Median based on very low numbers of cases within this category.
†95% confidence interval assessed by MedCalc.
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